新基医药咨询

Celgene Pharmaceuticals Information Consulting (Shanghai) Co., Ltd. is the Chinese subsidiary of Celgene Corporation, which was acquired by Bristol Myers Squibb (BMS) in 2019. Established in 2017 and headquartered in Shanghai, the company serves as the local entity responsible for clinical development, regulatory affairs, and medical consulting for Celgene's innovative pipeline in China. It manages clinical trials and regulatory submissions for key therapeutic assets, including Reblozyl (luspatercept) for beta-thalassemia, Inrebic (fedratinib) for myelofibrosis, and Zeposia (ozanimod) for inflammatory bowel diseases. Following the acquisition, the company operates under the broader umbrella of BMS China, aligning its clinical and commercial strategies to bring advanced oncology, hematology, and immunology therapies to Chinese patients.